AstraZeneca和Daichi Sankyo撤回欧盟对肺癌药物Dato-DXd的申请,面临挫折。 AstraZeneca and Daiichi Sankyo withdraw EU application for lung cancer drug Dato-DXd, facing a setback.

根据欧洲药物管理局的反,AstraZeneca和Daiichi Sankyo已撤回了对肺癌治疗药物Dato- DXd在欧盟的营销批准申请. AstraZeneca and Daiichi Sankyo have withdrawn their application for marketing approval of the lung cancer treatment Dato-DXd in the EU, following feedback from the European Medicines Agency. 尽管遭遇这一挫折,各公司仍计划继续努力将这一药物带给患肺癌的欧盟病人。 The companies plan to continue working towards bringing the drug to EU patients with lung cancer despite this setback.